acadia pharmaceuticals inc (ACAD) Key Developments
ACADIA Pharmaceuticals Inc. Appoints Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2015
Jun 19 15
ACADIA Pharmaceuticals Inc. has appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2015 at the annual general meeting held on June 15, 2015.
ACADIA Pharmaceuticals Inc. Presents Integrated Efficacy and Tolerability Data from its Phase III Program with NUPLAZID™
Jun 16 15
ACADIA Pharmaceuticals Inc. announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. An integrated analysis was performed on efficacy and tolerability data from two six-week Phase III placebo-controlled clinical trials with NUPLAZID (40 mg) in Parkinson’s disease psychosis (PDP). In this large pooled sample of 268 patients from North America, NUPLAZID showed highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale (p2A receptors that play an important role in psychosis. ACADIA has reported positive Phase III trial results with NUPLAZID, which has the potential to be the first drug approved in the United States for psychosis associated with Parkinson’s disease. NUPLAZID is administered orally once-a-day. ACADIA discovered NUPLAZID and holds worldwide rights to this new chemical entity. The trade name NUPLAZID has been provisionally accepted by the FDA.
ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM
May 26 15
ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.
ACADIA Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 7 15
ACADIA Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaborative revenues of $4,000 against $30,000 a year ago. Loss from operations was $40,552,000 against $17,958,000 a year ago. Net loss was $40,375,000 against $17,828,000 a year ago. Net loss per common share, basic and diluted was $0.40 against $0.19 a year ago.
ACADIA Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM
May 6 15
ACADIA Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Stephen R. Davis, Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Executive Vice President.